Small longitudinal study of serum anticholinergic activity and cognitive change in community-dwelling older adults

American Journal of Geriatric Psychiatry

Volumn 23, Issue 3, 2015, Pages 326-329

  Kashyap, Mandavi ^a   Mulsant, Benoit H ^b   Tannenbaum, Cara ^c,d  

^a AIMST UNIVERSITY   (Malaysia)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d CENTRE DE RECHERCHE   (Canada)

Author keywords

anticholinergic; older adults; SAA

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; QUINUCLIDINYL BENZILATE; TRITIUM;

AGED; ANTICHOLINERGIC EFFECT; ARTICLE; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; DISEASE ASSOCIATION; DSM-5; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; PROSPECTIVE STUDY; BLOOD; CASE CONTROL STUDY; DEMOGRAPHY; MILD COGNITIVE IMPAIRMENT; RADIOASSAY; URINARY INCONTINENCE;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CHOLINERGIC ANTAGONISTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MILD COGNITIVE IMPAIRMENT; QUINUCLIDINYL BENZILATE; RADIOLIGAND ASSAY; RESIDENCE CHARACTERISTICS; TRITIUM; URINARY INCONTINENCE;

EID: 84928153274     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2014.09.009     Document Type: Article

References (12)

1. Carnahan RM, Lund BC, Perry PL, et al: A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice. Psychopharmacol Bull 2002; 36:24-39
2. Cox EA, Kwatra SG, Shetty S, et al: Flaws in the serum anticholinergic activity assay: implications for the study of delirium. J Am Geriatr Soc 2009; 57:1707-1736
3. Kersten H, Wyller TB: Anticholinergic drug burden in older people's brain-how well is it measured? Basic Clin Pharmacol Toxicol 2014; 114:151-159
4. Boustani M, Campbell N, Munger S, et al: Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 2008; 4:311-320
5. Chew ML, Mulsant BH, Pollock BG, et al: Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008; 56:1333-1341
6. Mangoni AA, van Munster BC, Woodman RJ, et al: Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am J Geriatr Psychiatry 2013; 21: 785-793
7. Flacker JM, Wei JY: Endogenous anticholinergic substances may exist during acute illness in elderly medical patients. J Gerontol A BiolSci Med Sci 2001; 56:M353eM355
8. Tune L, Coyle JT: Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch Gen Psychiatry 1980; 37:293-297
9. Kashyap M, Belleville S, Mulsant B, et al: Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline. J Am Geriatr Soc 2014; 62:336-341
10. Mulsant BH, Pollock BG, Kirshner M, et al: Serum anticholinergic activity in a community-based sample of older adults. Arch Gen Psychiatry 2003; 60:198-203
11. Kersten H, Molden E, Tolo IK, et al: Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. J Gerontol A Biol SciMed Sci 2013; 68:271-278
12. Gao S, Unverzagt FW, Hall KS, et al: Mild cognitive impairment, incidence, progression, and reversion: findings from a community-based cohort of elderly African Americans. Am J Geriatr Psychiatry 2014; 22:670-681